Loading provider…
Loading provider…
Hematology & Oncology Physician in Hollywood, FL
NPI: 1245225143Primary Practice Location
MEMORIAL HOSPITAL PEMBROKE
7800 Sheridan St, Pembroke Pines, FL
Primary Employer
Memorial Hospital Miramar - Medical Offices
mhs.net
HQ Phone
Get MD Atif's Phone Numberphone_androidMobile
Get MD Atif's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
1991 - 2026
MO State Medical License
2008 - 2018
NY State Medical License
2002 - 2018
KS State Medical License
2011 - 2017
NC State Medical License
1991 - 2009
MI State Medical License
1992 - 1993
LA State Medical License
1990 - 1992

American Board of Internal Medicine
Medical Oncology

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology
University of Miami/Jackson Health System
Fellowship • Hematology and Medical Oncology
1988 - 1992
American University of Beirut Faculty of Medicine
Medical School
Until 1983
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 101 | 224 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 17 | 23 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 13 | 18 |
Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications.
Pancreatic adverse events in patients treated with immune checkpoint inhibitors.
Authors: Brian Hunis, Jennifer Zikria, Caroline Hana, Matthew Salzberg
Journal: JGH Open
Publication Date: 2023-02-06
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Temozolomide, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Veliparib, OTHER: Placebo Administration
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Nivolumab, BIOLOGICAL: Ipilimumab
Lead Sponsor: Sellas Life Sciences Group
Collaborators: Merck Sharp & Dohme LLC, LumaBridge
Intervention / Treatment: BIOLOGICAL: pembrolizumab, BIOLOGICAL: GM-CSF, OTHER: Montanide, BIOLOGICAL: galinpepimut-S